Plaque debris

Plaque debris is not a single molecular target but rather a heterogeneous mixture of biological materials released from the rupture or mechanical disruption of pathological deposits, most commonly atherosclerotic plaques in the vasculature or amyloid plaques in the brain. In the cardiovascular context, this debris consists of cholesterol crystals, necrotic core fragments, calcified particles, and fibrin, which can lead to distal embolization, microvascular obstruction, and myocardial or cerebral infarction (Topol & Teirstein, 2015, Textbook of Interventional Cardiology). In neurobiology, plaque debris refers to the remnants of amyloid-beta aggregates that are processed by microglia during natural or antibody-mediated clearance (Hardy & Selkoe, 2002, Science). Because it is a physical byproduct of disease rather than a specific protein or receptor, it is not targeted by traditional small-molecule drugs in a lock-and-key fashion. Instead, therapeutic strategies focus on stabilizing the parent plaque to prevent debris formation (e.g., statins), using embolic protection devices to capture debris during surgery, or enhancing the phagocytic activity of macrophages and microglia to clear the material. Consequently, while clinically significant, plaque debris does not meet the criteria for a canonical therapeutic target molecule.

Other names

Atherosclerotic debrisEmbolic debrisNecrotic core debrisAmyloid debris

Not applicable as a molecular target; typically managed via mechanical filtration (embolic protection devices) or phagocytic clearance.